Remove 2021 Remove Food and Drug Administration Remove Pharmacology
article thumbnail

Early diagnosis in Alzheimer’s disease: A first step towards better care

Clarivate

Though there is no cure for the disease, people with Alzheimer’s can receive personalized, multimodal care and support to delay deterioration of their functional status and quality of life and alleviate the burden imposed on their care partners (Emblad, 2021; Bayly, 2021; Xiang, 2024). Currently, of the eight drugs approved by the U.S.

article thumbnail

The future of medical cannabis development in Europe

European Pharmaceutical Review

3 With established drug development pathways, we are accustomed to a rigid structure of translation from bench to bedside. It is estimated that only one in 10 drugs that enter Phase I trials are subsequently licensed by the US Food and Drug Administration (FDA).

Medical 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Pharma Injecting Life into Digital Health Amidst Funding Downturn

MedCity News

digital health sector plummeted to $15 billion from more than $29 billion in 2021, according to Rock Health. billion in 2021. And in the first quarter of this year, the largest Series A ever in digital health ($203M) went into a company accelerating clinical trials and drug development. digital health at $17.7

Pharma 108
article thumbnail

Patents: a necessary evil?

European Pharmaceutical Review

1 However, patent protection for pharmaceutical products is an economic trade-off between providing monopoly rights that incentivise development of future products and permitting higher drug prices to recoup the investment. 4 The initial patents are usually filed during drug discovery. The patent will typically expire after 20 years.

article thumbnail

Navigating the unique CMC challenges of oral anaerobic live biotherapeutics

European Pharmaceutical Review

The development of drug products containing live anaerobic bacterial strains as the active pharmaceutical ingredient and where potency and shelf-life is typically associated with viable cell quantification, poses unique challenges when compared to both small and large molecule development therapeutics.

article thumbnail

Paving the way for anti-Abeta active immunotherapy

European Pharmaceutical Review

Limitations of monoclonal antibody therapies Regulatory approvals from the US Food and Drug Administration (FDA) for aducanumab and lecanemab – and likely very soon for donanemab also – opened a route for different therapeutic modalities and other relevant disease targets, such as tau. Landry I, Kanekiyo M, Aluri J, et al.

article thumbnail

Beyond animal testing: the rise of organs-on-chips technology

Clarivate

Food and Administration (FDA) approval, a change long sought by animal welfare organizations. Drugs can be now cleared for human trials using non-animal technologies developed over the last 10-15 years. Food and Drug Administration, 2023). Then, of course, there are the ethical considerations.